News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
    • MS Advanced Practice Providers
  • Movement Disorders
    • Parkinson Disease
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
AANEM 2025|
ECTRIMS 2025|
MDS 2025|
NSGC 2025
Advertisement

Felicia C. Goldstein, PhD

Advertisement

Articles by Felicia C. Goldstein, PhD

Controversy Continues Regarding PPI Use and Dementia

ByFelicia C. Goldstein, PhD,Heidi Anne Duerr, MPH
July 6th 2017

A dementia expert addresses current controversies on proton pump inhibitors.

Advertisement

Latest Updated Articles

  • Controversy Continues Regarding PPI Use and Dementia
    Controversy Continues Regarding PPI Use and Dementia

    Published: July 6th 2017 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

FDA Approves Intrathecal Version of Zolgensma, Ozempic Falls Short in EVOKE Trials, Asundexian Meets End Point in Stroke Prevention Trial

2

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission

3

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease

4

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials

5

NeurologyLive® Brain Games: November 30, 2025

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us